# Biochemical analysis of a TrkB receptor mutation that causes a developmental epileptic encephalopathy

**Authors:** Yang Zhong Huang, Cormic McNamara, James O. McNamara

PMC · DOI: 10.1016/j.jbc.2026.111152 · The Journal of Biological Chemistry · 2026-01-10

## TL;DR

A mutation in the TrkB receptor causes a severe brain disorder by altering protein structure and reducing its function.

## Contribution

The study identifies a novel disulfide bond in a TrkB mutation linked to developmental epileptic encephalopathy.

## Key findings

- The Y434C mutation leads to low levels of mature TrkB protein and abnormal protein forms.
- Disulfide bonds between mutant TrkB proteins cause structural changes and increased proteolysis.
- Reduced TrkB signaling and proteolytic fragments may contribute to disease symptoms.

## Abstract

TrkB, a receptor tyrosine kinase encoded by gene NTRK2, is essential for diverse biological processes in both the developing and mature mammalian nervous systems. Whole exome sequencing of children with developmental epileptic encephalopathy revealed an intriguing syndrome caused by a rare de novo recurrent variant of TrkB, namely Y434C. Investigating the biochemical properties of the Y434C mutant protein is an important initial step toward understanding how this mutation causes this devastating disease. This led us to establish and characterize multiple cell lines stably expressing mouse WT or Y434C TrkB. In comparison to WT, Y434C mutant cell lines expressed low to undetectable levels of mature form (145 kDa) of TrkB protein and varying levels of mutant forms migrating at sizes ranging from 40 to 110 kDa. Y434C mutant cell lines exhibited striking impairments of brain-derived neurotrophic factor–mediated activation of TrkB signaling. Reducing agents reduced high molecular weight forms of Y434C protein multimers detected in protein gel electrophoresis, consistent with disulfide bond formation between the Y434C mutant proteins. We propose that conversion of tyrosine to cysteine at amino acid 434 results in a novel intermolecular disulfide bond between Y434C mutant proteins, thereby modifying their structure and enhancing their proteolytic digestion. The ensuing reductions of the mature form of TrkB likely underlie impaired TrkB signaling. The proteolytic fragments of TrkB may themselves have deleterious consequences, which contribute to the phenotypic manifestations of the Y434C TrkB mutation.

## Linked entities

- **Genes:** NTRK2 (neurotrophic receptor tyrosine kinase 2) [NCBI Gene 4915]
- **Proteins:** NTRK2 (neurotrophic receptor tyrosine kinase 2)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Ntrk2 (neurotrophic tyrosine kinase, receptor, type 2) [NCBI Gene 18212] {aka GP145-TrkB/GP95-TrkB, Tkrb, trk-B, trkB}, Tyro3 (TYRO3 protein tyrosine kinase 3) [NCBI Gene 22174] {aka Brt, Dtk, Etk-2, Rse, Sky, TK19-2}, NTRK1 (neurotrophic receptor tyrosine kinase 1) [NCBI Gene 4914] {aka MTC, TRK, TRK1, TRKA, Trk-A, p140-TrkA}, BDNF (brain derived neurotrophic factor) [NCBI Gene 627] {aka ANON2, BULN2}, EPHB2 (EPH receptor B2) [NCBI Gene 2048] {aka BDPLT22, CAPB, DRT, EK5, EPHT3, ERK}, PLCG1 (phospholipase C gamma 1) [NCBI Gene 5335] {aka IDAA, NCKAP3, PLC-II, PLC1, PLC148, PLCgamma1}, NGLY1 (N-glycanase 1) [NCBI Gene 55768] {aka CDDG, CDG1V, PNG-1, PNG1, PNGase}, POTEF (POTE ankyrin domain family member F) [NCBI Gene 728378] {aka A26C1B, POTE2alpha, POTEACTIN}, Bdnf (brain derived neurotrophic factor) [NCBI Gene 12064], BLNK (B cell linker) [NCBI Gene 29760] {aka AGM4, BASH, BLNK-S, LY57, SLP-65, SLP65}, NTRK2 (neurotrophic receptor tyrosine kinase 2) [NCBI Gene 4915] {aka DEE58, EIEE58, GP145-TrkB, OBHD, TRKB, trk-B}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}
- **Diseases:** Alzheimer's (MESH:D000544), depression (MESH:D003866), cognitive deficits (MESH:D003072), Huntington's diseases (MESH:D006816), epileptic encephalopathy (MESH:D001927), WT (MESH:D009396), Developmental Epileptic Encephalopathy (MESH:C562695), autistic behavior (MESH:D001321), intellectual and motor disability (MESH:D008607), impairments of vision (MESH:D014786), neurodegenerative diseases (MESH:D019636), neuropsychiatric disorders (MESH:D001523), Epileptic seizures (MESH:D004827)
- **Chemicals:** NP-40 (MESH:C010615), penicillin (MESH:D010406), streptomycin (MESH:D013307), disulfide (MESH:D004220), Laemmli buffer (MESH:C088816), PBS (MESH:D007854), Lipofectamine (MESH:C086724), CO2 (MESH:D002245), mannose (MESH:D008358), DTT (MESH:D004229), glycans (MESH:D011134), geneticin (MESH:C010680), NaCl (MESH:D012965), iodoacetamide (MESH:D007460), SDS (MESH:D012967), sodium deoxycholate (MESH:D003840), Dulbecco (-), cysteines (MESH:D003545), thiol (MESH:D013438)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** cysteine was substituted for tyrosine, Y434
- **Cell lines:** HEK293T — Homo sapiens (Human), Transformed cell line (CVCL_0063), HEK Y434C — Homo sapiens (Human), Xeroderma pigmentosum, complementation group D, Finite cell line (CVCL_L754), 293 — Homo sapiens (Human), Transformed cell line (CVCL_0045)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12876826/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12876826/full.md

## References

22 references — full list in the complete paper: https://tomesphere.com/paper/PMC12876826/full.md

---
Source: https://tomesphere.com/paper/PMC12876826